ClinConnect ClinConnect Logo
Search / Trial NCT02333955

A Phase 2 Extension of Study GCS-100-CS-4003

Launched by LA JOLLA PHARMACEUTICAL COMPANY · Jan 7, 2015

Trial Information

Current as of July 23, 2025

Withdrawn

Keywords

ClinConnect Summary

Galectin-3 contributes to fibrosis, is elevated in patients with ESRD, and correlates with adverse outcomes (de Boer et. al., 2011, Dang et. al., 2012, Fernandes Bertocchi et. al., 2008, Henderson et. al., 2008). Animal models with genetic knockout of galectin-3 demonstrate a reduction in structural and functional deficits in the kidney (Dang et. al., 2012, Fernandes Bertocchi et. al., 2008, Henderson et. al., 2008). GCS-100 is a galectin-3 antagonist that has been shown to reduce fibrosis pre-clinically. Based on the role of galectin-3 and fibrosis in kidney disease, the Sponsor believes G...

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • 1. Subject is capable of understanding the purpose and risks of the study and is able to provide written informed consent
  • 2. Subject was enrolled in GCS-100-CS-4003.
  • Exclusion Criteria:
  • 1. Subject experienced a Grade 3 or worse adverse event related to GCS-100 in clinical study GCS-100-CS-4003.
  • 2. Systolic blood pressure ≤90 mmHg and ≥160 mmHg and diastolic blood pressure ≤40 mmHg and ≥100 mmHg at screening
  • 3. Subject has clinical laboratory values of:
  • Hemoglobin: ≤9 g/dL
  • Total bilirubin: \>1.5X the upper limit of normal (ULN)
  • ALT and/or AST: \>2.5X ULN
  • 4. Subject has a concomitant disease or condition, including laboratory abnormalities, which, in the opinion of the investigator, could interfere with the conduct of the study or put the subject at unacceptable risk.
  • 5. Subject who may require renal replacement therapy within the next 2 months, at the discretion of the investigator.

About La Jolla Pharmaceutical Company

La Jolla Pharmaceutical Company is a biopharmaceutical firm dedicated to the development of innovative therapies for patients with severe and life-threatening diseases. With a focus on advancing novel treatments through rigorous clinical trials, the company leverages cutting-edge science and technology to address unmet medical needs in areas such as kidney diseases and autoimmune disorders. Committed to improving patient outcomes, La Jolla collaborates with healthcare professionals and research institutions to bring transformative therapies from the laboratory to the clinic, ensuring a patient-centered approach throughout the development process.

Locations

Denver, Colorado, United States

La Mesa, California, United States

Tempe, Arizona, United States

Asheville, North Carolina, United States

San Antonio, Texas, United States

Patients applied

0 patients applied

Trial Officials

George Tidmarsh, MD, PhD

Study Director

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials